price
corpor client peel hunt
posit updat uk public healthcar sector
budget chancellor confirm pre-announc commit boost nh fund england later
least use mental health servic
nh genom project uk sharpen edg patient data ai relat opportun
look leverag nh enviabl data set nh name seven geograph region trust hub deliv new
secretari target sequenc million patient genom within five year
uk independ provid outsourc nh servic agre provid non-emerg orthopaed oper
nh hospit first time deal see nh privat provid act joint entiti significantli reduc wait
list patient take advantag synergi better plan
pre-christma catalyst univers
hikma due releas trade statement capit market day novemb event expect ceo siggi olafsson
set vision group includ detail ambit potenti also mid-term perform kpi hikma
guidanc higher profit inject busi look conserv us see scope guidanc uplift hikma
outperform ytd bar high guidanc upgrad posit mid-term outlook could still send share higher
udg de-rat strongli back temporari headwind caus histor trade premium peer collaps
believ fear overdon manag reiter guidanc earli august visibl would reason
good low base effect carry-ov contract sharp also expect robust outlook statement come
year condit met udg enjoy good relief ralli result announc novemb
clinigen novemb good opportun manag provid colour integr strategi
perform recent acquisit includ csm iqon believ demonstr clinigen abil drive growth
synergi posit return recent deal trigger posit momentum share price
document must treat market commun purpos direct prepar accord legal requir
design promot independ research subject prohibit deal ahead dissemin invest research
case miss key healthcar news flow talk
clinigen growth stock valu multipl
recent updat clinigen forecast reflect result latest acquisit revis valuat clinigen offer mid-teen ebitda
compound-annual-growth-rate yield upsid target price yet trade price-to-earnings believ ytd contract clinigen multipl
due unfound fear underli growth execut former allay modest beat vs consensu confirm
outlook deliv result septemb latter dispel clinigen strong execut recent deal see septemb csm
iqon acquisit valu accret clinigen target greater pre-synergi well wacc believ depress
multipl offer good entri point uniqu growth stori ahead novemb
convatec downgrad forecast back profit warn
convatec announc profit warn mid-octob updat model reflect revis guidanc cut revenu estim
along conserv margin forecast reduc ep period put us consensu
come sinc publish revis multiples-bas target price suggest modest valuat upsid despit conserv forecast assumpt
low visibl turnaround prospect keep us side-lin
releas second episod practition podcast seri ai artifici intellig applic healthcar sector episod
team peel hunt technolog analyst describ term ai ml machin learn dl deep learn realli mean also address
opportun healthcar landscap tradit brute forc ai approach may left behind next rapidli develop field clinic
ai remind first episod review complex nh structur describ problem health system face discuss ai
applic might help burden
updat model follow vectura interim result main chang revenu mix higher flutiform product suppli off-set
lower royalti contribut leav top-lin estim broadli unchang howev result lower gross margin reduc adjust ebitda
next five year turn led us trim target price still lack convict abil identifi near-
term catalyst materi improv investor sentiment share backdrop low appetit pipeline-driven stori healthcar current
therefor remain hold despit impli upsid estim fair valu
sensyn dock station nh pharma
initi sensyn health buy recommend tp sensyn dock station nh pharma aim acceler
discoveri research improv care analysi real world evid anonymis patient data compani alreadi shown patient benefit
uk hospit power analysi pharma august rais success ipo nh one biggest collect single-
provid data cradle-to-grav popul peopl sensyn alreadi sign four strateg agreement nh trust demonstr
role trust partner sustain monetis uk sovereign asset unrival nh data-set
valu multipl
convatec hold first
succeed time
healthcar ai
healthcar ai
model valuat post
circassia buy hold
upgrad buy deliv
sale
coverag
corpor client peel hunt
chart one-month ytd total return
vectura announc result data
oxb announc partner/spin-out one in-hous product candid
udg underappreci driver growth
udg due report result novemb meet guidanc cc ep growth
robust outlook beyond could see strong bounc share
like udg strong posit stabl high-vis healthcar servic industri udg undergo
rapid transform align busi myriad opportun aris shake-up
dispos udg suppli chain activ recent non-cor
aquil increas focu faster grow higher-valu add servic rais udg balanc sheet
option high qualiti high growth high margin sharp ashfield commun advisori
busi account oper profit busi udg invest drive
buy recommend valuat methodolog give explicit credit udg strong balanc sheet
demonstr track record value-enhanc invest
clinigen growth stock valu multipl
estim clinigen offer mid-teen ebitda compound-annual-growth-rate yield upsid target
price yet trade price-to-earnings believ ytd contract clinigen multipl due
unfound fear underli growth execut view overdon multipl
come despit flat earn momentum see pg also see septemb csm iqon acquisit
valu accret clinigen target greater pre-synergi well wacc
clinigen novemb good opportun manag provid colour integr
strategi perform recent deal demonstr abil drive growth synergi
posit return along depress multipl offer good entri point uniqu growth
oxford biomedica axov novarti bioverativ deal prove platform
oxford biomedica offer low-risk capex-light pure play gene cell therapi revolut
equiti place earlier year fund expans bioprocess facil three major deal novarti
bioverativ axov prove oxb platform well posit growth
importantli believ recent deal axov along major bioverativ novarti
collabor prove success oxford biomedica gene therapi lentivir vector platform believ
translat sizeabl near-term contract partner oxb grant
exclus world-wid licens axov develop commercialis oxb intern pipelin gene therapi
parkinson axo-lenti-pd oxb say expect sign anoth deal intern pipelin
end
corpor client peel hunt
fda approv deal us exposur
tabl recent deal within healthcar sector
chart us exposur compani within coverag measur revenu
gener us
chart us healthcar sub-sector perform vs wider
chart uk healthcar perform vs us eu rel perform
share
tabl valuat comparison tabl uk small mid-cap healthcar peel hunt coverag
corpor client peel hunt
multipl comparison complic heterogen sector mani early-stag player
chart ev/sal rel sale growth
chart ev/sal rel sale growth
chart ev/ebitda rel ebitda growth
chart per rel ep growth
chart ev/ebitda rel ebitda growth
chart per rel ep growth
multipl present profit name coverag
price-to-earnings ev/ebitda
chart abc multipl forward price-to-earnings ev/ebitda
chart btg multipl forward price-to-earnings ev/ebitda
chart clin multipl forward price-to-earnings ev/ebitda
chart ctec multipl forward price-to-earnings ev/ebitda
chart hik multipl forward price-to-earnings ev/ebitda
chart spi multipl forward price-to-earnings ev/ebitda
chart udg multipl forward price-to-earnings ev/ebitda
chart vec multipl forward price-to-earnings ev/ebitda
corpor client peel hunt
corpor client peel hunt
chart uk healthcar equip servic uk healthcar perform vs uk
corpor client peel hunt
chart us life scienc tool index use proxi reflect wider perform sub-
chart us med-tech index use proxi reflect wider perform sub-sector
corpor client peel hunt
chart us index use proxi reflect wider perform sub-sector
corpor client peel hunt
symposium advanc wound
btg interim result six month end
recommend distribut octob
research publish last day
recommend structur distribut
peel hunt recommend structur follow
buy expect absolut price perform month
add rang expect absolut price perform month
hold rang expect absolut price perform month
reduc rang expect absolut price perform month
sell expect absolut price perform month
nb recommend primari driver analyst view target price may vari structur due market condit risk profil compani capit return
